| Sep 9 |
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
|
| Sep 9 |
Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
|
| Sep 8 |
Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
|
| Sep 6 |
3 Market-Beating Stocks to Buy for Less Than $100
|
| Sep 5 |
AstraZeneca Employees Held in China for Data Privacy, Drug-Import Investigations
|
| Sep 5 |
AstraZeneca In Trouble For Employee Detentions in China Over Illegal Activities
|
| Sep 5 |
AstraZeneca Options Trading: A Deep Dive into Market Sentiment
|
| Sep 5 |
China Detains AstraZeneca Employees Over Alleged Transport of Unapproved Drug
|
| Sep 5 |
AstraZeneca says ‘small number’ of employees under investigation in China
|
| Sep 5 |
AstraZeneca staff detained in China amid claims of illegal drug imports
|
